Coulter, Joshua
Whichello, Chiara
Heidenreich, Sebastian
Hauber, Brett
Michaels-Igbokwe, Christine
Cappelleri, Joseph C.
Peyrani, Paula
Vespa Presa, Jessica
Venkatraman, Malavika
Schley, Katharina http://orcid.org/0000-0002-0975-4154
Funding for this research was provided by:
Pfizer
Article History
Accepted: 8 February 2024
First Online: 23 February 2024
Declarations
:
: Joshua Coulter, Brett Hauber, Joseph C. Cappelleri, Paula Peyrani, Jessica Vespa Presa and Katharina Schley are employees and may hold stocks or stock options in PfizerĀ Inc.. Chiara Whichello, Sebastian Heidenreich, Christine Michaels-Igbokwe, and Malavika Venkatraman are employees of Evidera, which was paid by Pfizer for the development of this manuscript.
: The study was conducted in accordance with accepted research practices described in Good Practices for Outcomes Research, issued by the International Society for Pharmacoeconomics and Outcomes Research. Compliance with regulatory standards assured that the rights, safety, and well-being of participants were protected and that the study data were credible and responsibly reported. This study was designed, implemented, and reported in accordance with US ethical guidelines and with the ethical principles laid down in the Declaration of Helsinki. The study protocol was submitted to Ethical and Independent Review Services, a fully accredited institutional review board, for central ethical approval. Institutional Review Board approval was granted on 29 March 2022 (reference: 22049-01).
: Participants provided oral and digitally collected written consent.
: Not applicable.